Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Alphamab Starts Clinical Trial on Its First Novel Biologics KN015, a Long-acting FSH, for In Vitro Fertilization (IVF)

Suzhou Alphamab
Posted on: 25 Oct 16

SUZHOU, China--(BUSINESS WIRE)--Suzhou Alphamab Co., Ltd. announced today that it is initiating a Phase I trial for its leading proprietary program KN015 in China, marking a key milestone achievement for Alphamab in its pursuit of developing innovative biologics medicine.

KN015 is a long-acting human follicle-stimulating hormone (FSH). FSH is used clinically for infertility treatment, i.e. controlled ovarian stimulation (COS) in combination with a GnRH (Gonadotropin releasing hormone) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology program. So far all the approved FSH products, such as Gonal-F and Elonva, need multiple injections in the treatment cycle. The current market sales for FSH products in China is over $330 million, and is forecast to grow significantly with the increasing infertility population, which is primarily attributed to environmental changes, higher stress level, and pregnancy at an older age.

In the preclinical studies, KN015 has shown longer in vivo half-life and similar bio-activity as compared to Gonal-F. Thus this product profile makes feasible a single subcutaneous injection of KN015 in a COS treatment cycle.

“We are very excited about moving our first proprietary biologics into clinical testing,” said Dr. Ting Xu, Chairman and CEO of Alphamab. “With the superior efficacy and safety shown in preclinical studies, KN015 could offer patients the important benefits in treatment compliance, as well as reduction in stress and cost attributed to an otherwise daily injection of short-acting FSH. We very much look forward to working with clinical experts in this field to develop KN035 as a valuable addition to the currently available treatments.”

About Suzhou Alphamab Co., Ltd.

Suzhou Alphamab Co., Ltd., founded in 2009, is a leading biotechnology company in China focused on the discovery, development and manufacture of innovative biologics therapeutics. With multiple in-house proprietary platforms in protein engineering, antibody screening and bi-specifics, Alphamab and its subsidiaries have created a robust pipeline of over 20 innovative biologics programs in immune-oncology, infertility, infectious diseases and several other areas. Alphamab is striving to develop 1st-in-class or best-in-class medicine to address unmet medical needs globally.

Visit http://www.alphamab.com for more information.

Contacts

Suzhou Alphamab Co., Ltd.
Junhong Zhang, +86-512-65951826
junhongzhang@alphamab.com

For more information:
www.businesswire.com/news/home/20161024005613/en/Alphamab-Starts-Clinical-Trial-Biologics-KN015-Long-acting

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.